skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Safety and Efficacy of Y-90 Radioembolization After Prior Major Hepatic Resection

Journal Article · · Cardiovascular and Interventional Radiology
; ; ; ;  [1];  [2];  [3]; ; ;  [1]
  1. RWTH Aachen University Hospital, Department of Diagnostic and Interventional Radiology (Germany)
  2. RWTH Aachen University Hospital, Department of General Surgery (Germany)
  3. RWTH Aachen University Hospital, Department of Nuclear Medicine (Germany)

PurposeTo evaluate the safety and efficacy of yttrium-90 radioembolization (RE) following left or right hepatic lobectomy.Materials and MethodsBetween 2011 and 2016, 15 patients underwent RE with Y90-resin microspheres following right (8/15) or left (7/15) hepatic lobectomy. In eight patients, the whole liver remnant was treated during a single session, whereas the remaining seven patients received up to 3 selective RE at 1- to 2-month intervals. The administered patient activity was calculated based on the body surface area (BSA) method in all cases. In addition, CT-based volumetry of the liver remnant was performed and used to calculate the absorbed liver dose. Patient follow-up data were retrospectively analyzed regarding signs of radioembolization-induced liver disease (REILD), defined as occurrence of bilirubin >3.0 mg/dl and ascites within 1–2 months after treatment without tumor progression or bile duct occlusion.ResultsThe mean volume of the liver remnant was 1.471 ± 341 ml, the mean administered amount of activity amounted to 1.31 ± 0.74 GBq, and the calculated mean absorbed dose was 42.8 ± 20.6 Gy. The early response to treatment was generally positive, with only one patient showing signs of progressive disease of the treated area on follow-up examinations within the first 2 months post-RE. None of the 15 patients developed a REILD.ConclusionY-90 radioembolization following extended hepatic lobectomy appears to be safe and effective. Although the standard BSA-based dosing seems to suffice to avoid REILD, it results in quite variable liver doses due to variable hypertrophy of the liver remnant post-hepatectomy. Level of Evidence: Level IV, Case series.

OSTI ID:
22756472
Journal Information:
Cardiovascular and Interventional Radiology, Vol. 40, Issue 8; Other Information: Copyright (c) 2017 Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); Article Copyright (c) 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); http://www.springer-ny.com; Country of input: International Atomic Energy Agency (IAEA); ISSN 0174-1551
Country of Publication:
United States
Language:
English